I do believe tumor agnostic indication is in play for UK approval and they will need Eden to meet that demand. For me, this explains the lengthy process. Is your cancer diagnosis more important than mine? If the UK approved DCVAX for only newly diagnosed GBM and RGBM, this would be discrimination against the UK citizens who have been diagnosed with other tumors with a poor prognosis, such as pancreatic, etc. As a regulator you cannot deny access to a treatment that offers real, long term survival vs current standard of care just because you have a different cancer, but just as deadly nonetheless. There would be serious public backlash. Linda Powers is very careful in the words she chooses in her PRs. Having read them throughout the years, her tone is very confident in recent releases. Dominant Franchise, Significant Ramp up in production come to mind. She is a big picture, long term thinker with a strategic mind. I see the most minute inconsequential details hashed and rehashed by the cabal on this board. Can't see the forest for the trees kind a thing. When you arrive at your destination most people won't care how you got there, just that you did.
Market Data 
Markets 
